Plain-English translation of NCT06990399 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether a new medication called can help reduce swelling in the macula of your eye when that swelling is caused by inflammation. The medication is given as an injection directly into the eye. Researchers want to find out if this treatment can improve vision and reduce the fluid buildup that's causing the swelling.
Many people experience swelling in the macula due to inflammatory eye conditions, and this can blur or distort vision. There's a need for better treatment options, and this medication is designed to target the inflammation directly and reduce the fluid buildup.
You likely qualify if…
You likely don't qualify if…
You will receive an injection of the medication (or a sham injection if you're in the control group) into your eye once a month for six months, then the schedule may be adjusted based on how you respond. Throughout the study, you'll have eye exams and imaging tests to measure the swelling and check your vision. The study involves regular visits to the clinic over several months to monitor your progress and safety.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States